Novel Immunotherapy for Primary Hemophagocytic Lymphohistiocytosis
Results of a study evaluating the safety and efficacy of a promising new agent were presented at ASH 2018. (Source: CancerNetwork)
Source: CancerNetwork - December 7, 2018 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news

Roche wins key lung cancer combo approval
Roche Holding ’s Tecentriq immunotherapy, in combination with Avastin and chemotherapy, won U.S. FDA approval as a first-line treatment for a type of lung cancer. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 7, 2018 Category: Pharmaceuticals Source Type: news

AstraZeneca's Imfinzi fails to meet main goals in head and neck cancer study
AstraZeneca Plc's immunotherapy Imfinzi did not meet the main goals of a late-stage study testing the drug as a treatment for advanced head and neck cancer, the London-listed drugmaker said on Friday. (Source: Reuters: Health)
Source: Reuters: Health - December 7, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Roche's lung cancer combo treatment wins FDA approval
Swiss drugmaker Roche Holding AG said on Thursday that its Tecentriq immunotherapy in combination with chemotherapy was approved by the U.S. Food and Drug Administration as a first-line treatment for a form of lung cancer. (Source: Reuters: Health)
Source: Reuters: Health - December 6, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Putting the brakes on tumor stealth
(Monash University) New research undertaken at Monash University has shed new light on how some cancers are able to escape our immune system. The findings have significant implications for the burgeoning field of cancer immunotherapy, an approach that is focused on harnessing the remarkable power of our own immune system to seek out and destroy cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 6, 2018 Category: Cancer & Oncology Source Type: news

Expanding the landscape of immunotherapy targets
(Source: ScienceNOW)
Source: ScienceNOW - December 6, 2018 Category: Science Authors: Charneski, C. A. Tags: twis Source Type: news

FDA gives Roche immunotherapy drug priority review
The FDA has awarded Roche an accelerated review of its immunotherapy drug, Tecentriq, to treat non small-cell lung cancer. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 5, 2018 Category: Pharmaceuticals Source Type: news

Ask the Doctors: How gut microbiome affects cancer treatment
According to Dr. Eve Glazier, the patients who responded best to treatment with a certain class of immunotherapy drugs were those with the more diverse and robust gut microbiomes.12/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - December 5, 2018 Category: Urology & Nephrology Source Type: news

The Future Of Cancer Care: A 50 Minute Discussion At Forbes
The future of cancer therapy, an analysis of how Immunotherapy has improved oncology outcomes for patients. This year's Forbes Summit highlighted both the difficulties, advancements and needs of the cancer care community in order to find the " cure " for cancer. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - December 5, 2018 Category: Pharmaceuticals Authors: Steve Brozak, Contributor Tags: NYSE:MRK NASDAQ:LOXO NASDAQ:ALLO Source Type: news

Roche's Tecentriq wins speedy U.S. FDA review for small cell lung cancer
Swiss group Roche Holding AG said on Wednesday its Tecentriq immunotherapy mixed with chemotherapy won priority review from the U.S. regulator for treating a type of lung cancer, a potential boost to the drug that has been trailing rivals' revenues. (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Roche's Tecentriq wins speedy U.S. review in small cell lung cancer
Roche's Tecentriq immunotherapy with chemotherapy won priority review in the United States for the initial treatment of extensive-stage small cell lung cancer (SCLC), the company said, setting up possible approval by March 18. (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Immunotherapy pioneers reveal updated efficacy data of tisagenlecleucel CAR T-cell therapy
(Children's Hospital of Philadelphia) Physician-scientists from Children's Hospital of Philadelphia presented updated efficacy and safety data on Kymriah (tisagenlecleucel, formerly CTL019) -- the first-ever FDA-approved personalized CAR T-cell gene immunotherapy for aggressive blood cancers, at the 60th American Society of Hematology annual meeting, as well as first-of-its-kind research on overcoming CAR T-cell resistance. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 4, 2018 Category: Cancer & Oncology Source Type: news

New cancer immunotherapy approach turns human cells into tiny anti-tumor drug factories
(University of California - San Diego) In lab and mouse experiments, UC San Diego School of Medicine researchers developed a method to leverage B cells to manufacture and secrete tumor-suppressing microRNAs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 4, 2018 Category: Cancer & Oncology Source Type: news

New cancer immunotherapy approach turns immune cells into tiny anti-tumor drug factories
(University of California - San Diego) In lab and mouse experiments, UC San Diego School of Medicine researchers developed a method to leverage B cells to manufacture and secrete tumor-suppressing microRNAs. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - December 4, 2018 Category: Biology Source Type: news

Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE ® Immunotherapies AMG 420 And AMG 330 At ASH 2018
Phase 1 Results of Amgen's BiTE® Platform in Heavily Pre-Treated Patients With Multiple Myeloma and Acute Myeloid Leukemia FDA Grants Fast Track Designation for AMG 420 THOUSAND OAKS, Calif., Dec. 3, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the first clinical results from studies evaluating investigational novel bispecific T cell engager (BiTE®) immunotherapies AMG 420 and AMG 330. In two separate Phase 1 dose escalation studies, AMG 420, which targets B-cell maturation antigen (BCMA), and AMG 330, which targets CD33, provided early evidence of tolerability and anti-tumor activity in pat...
Source: Amgen News Release - December 4, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Add-On Drugs Could Boost Efficacy, Tolerability of CAR T-Cell Therapies
(MedPage Today) -- Studies test addition of targeted agents, immunotherapy (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 3, 2018 Category: Hematology Source Type: news

Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 3, 2018 Category: Pharmaceuticals Source Type: news

Janssen Affiliate Cilag GmbH International Enters Worldwide Collaboration and License Agreement with argenx for Cancer Immunotherapy Cusatuzumab
Addition of investigational antibody cusatuzumab to robust oncology pipeline reflects Janssen's commitment to advance innovative therapies for blood cancers where unmet medical needs remain UG, Switzerland, December 3, 2018 -- (Healthcare Sales & Market... Biopharmaceuticals, Oncology, Licensing Cilag, argenx BVBA, argenx SE, cusatuzumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 3, 2018 Category: Pharmaceuticals Source Type: news

Norway biotech Ultimovacs plans IPO to develop cancer drug
Norway's Ultimovacs plans to raise around 700 million Norwegian crowns ($82 million) in an initial public offering in early 2019 to help fund the development of its immunotherapy cancer drug. (Source: Reuters: Health)
Source: Reuters: Health - December 3, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Experts in immunotherapy, medical physics, cervical cancer named 2018 ASTRO Gold Medalists
(American Society for Radiation Oncology) The American Society for Radiation Oncology (ASTRO) recently named three leaders in radiation oncology as the recipients of its Gold Medal award. Patricia Eifel, M.D., FASTRO, David Jaffray, Ph.D., and Ralph Weichselbaum, M.D., were awarded the highest honor bestowed upon ASTRO members and recognized for their achievements at ASTRO's 60th Annual Meeting in San Antonio. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 3, 2018 Category: International Medicine & Public Health Source Type: news

CNIO and Hospital 12 de Octubre extend effectiveness of immunotherapy to more lung cancer patients
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Combining immunotherapy with chemotherapy in patients with metastatic squamous cell carcinoma 'significantly increases' the survival of patients.Squamous cell carcinoma represents 20 percent to 30 percent of all cases of lung cancer and has a worse prognosis than other variants. It has the least amount of progress in terms of treatment.Patients who received chemotherapy and immunotherapy extended their survival by almost 16 months on average, compared to 11.3 months for those who received chemotherapy alone. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 3, 2018 Category: International Medicine & Public Health Source Type: news

Genetically engineered immune cells show promise for fighting relapsed blood cancer
(UNC Lineberger Comprehensive Cancer Center) At the 60th Annual American Society of Hematology Annual Meeting in San Diego on Monday, UNC Lineberger Comprehensive Cancer Center researchers presented preliminary results from a clinical study of an investigational cellular immunotherapy for Hodgkin lymphoma and non-Hodgkin lymphoma expressing the CD30 protein marker. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 3, 2018 Category: Cancer & Oncology Source Type: news

Combination immunotherapy shows high activity against recurrent Hodgkin lymphoma
(NYU Langone Health / NYU School of Medicine) A new combination of three drugs that harness the body's immune system is safe and effective, destroying most cancer cells in 95 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early-phase study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 3, 2018 Category: Cancer & Oncology Source Type: news

Dana-Farber researchers report clinical trial results in treatment of leukemia & lymphoma
(Dana-Farber Cancer Institute) New results from clinical trials of immunotherapy and experimental targeted agents for patients with leukemia and lymphoma are being presented by Dana-Farber Cancer Institute researchers at the ASH Annual Meeting. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 2, 2018 Category: Cancer & Oncology Source Type: news

The Future of HIV Treatment Might Not Involve Pills
HIV treatments have come a long way in the more than 30 years since the virus was first identified. Powerful antiretroviral drugs (ARVs) can now keep the virus controlled at levels that current tests cannot detect in the blood. Perhaps just as important, people who take these drugs diligently soon after they’re infected are unlikely to pass the virus to others. But the treatment isn’t perfect. Those with HIV need to take a pill every day for the rest of their lives, and even if they do, the virus can easily morph to become resistant to the drugs. That’s why patients on ARV treatment should faithfully moni...
Source: TIME: Health - December 1, 2018 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized healthytime HIV/AIDS onetime Source Type: news

Studies suggest immunotherapy adds punch to earlier attempts
(NYU Langone Health / NYU School of Medicine) New drugs that harness the body's immune system to destroy cancer cells appear to increase the effectiveness of later drug therapies for non-Hodgkin and Hodgkin lymphoma patients, new research suggests. This happens, scientists say, even for repeat drug therapies whose initial attempts failed to stop or reverse the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 1, 2018 Category: Cancer & Oncology Source Type: news

Year in Review: Pulmonology
(MedPage Today) -- As-needed asthma therapy, peanut oral immunotherapy, teen e-cig use made headlines in 2018 (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - November 30, 2018 Category: Allergy & Immunology Source Type: news

Study: Immunotherapy better than chemotherapy for subtype of head and neck cancer
(University of California - San Diego) A randomized clinical trial involving 97 medical centers in 20 countries, including Moores Cancer Center at UC San Diego Health, found that treating patients with head and neck cancer with the immunotherapy drug pembrolizumab is more effective and less toxic than standard chemotherapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 30, 2018 Category: International Medicine & Public Health Source Type: news

Immunotherapy keeps some advanced head and neck cancer patients alive for over three years
(Institute of Cancer Research) A new immunotherapy can greatly extend the lives of a proportion of people with advanced head and neck cancer, with some living for three years or more, a major new clinical trial reports.Overall, the drug pembrolizumab had significant benefits for patients, with 37 per cent of patients who received it surviving for a year or more, compared with only 26.5 per cent of those on standard care. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 30, 2018 Category: Cancer & Oncology Source Type: news

Free, publicly available health data proves to be research gold mine
(University of Calgary) Immunotherapy has become a popular treatment for some cancers. University of Calgary researchers discover how a set of genes, those associated with the extracellular matrix, had a direct connection to how cancer patients respond to immunotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 30, 2018 Category: Cancer & Oncology Source Type: news

5 Things to Know About Bladder Cancer 5 Things to Know About Bladder Cancer
From new immunotherapies to the role of the microbiome in cancer pathogenesis, here are the most important recent developments in bladder cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 29, 2018 Category: Consumer Health News Tags: Hematology-Oncology Article Source Type: news

Triple combination cancer immunotherapy improves outcomes in preclinical melanoma model
(Medical University of South Carolina) In adoptive cell transfer immunotherapy, T cells able to recognize a tumor are harvested, expanded in the laboratory, and then reintroduced to attack the tumor. However, they often do not persist long enough to finish the job. A triple combination regimen of adoptive T cell transfer, a PIM kinase inhibitor, and a PD1 inhibitor improved T cell persistence and tumor control in a mouse model of melanoma, report Medical University of South Carolina investigators. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 29, 2018 Category: International Medicine & Public Health Source Type: news

Cancer Research UK, the Francis Crick Institute and Bristol-Myers Squibb join forces
(Cancer Research UK) A 'rule book' to guide precision combination immunotherapies and to speed up the development of new lung cancer treatments will be created as part of a collaboration between Cancer Research UK, the Francis Crick Institute and Bristol-Myers Squibb, announced today (Friday). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 29, 2018 Category: Cancer & Oncology Source Type: news

Paradox: Obesity Promotes Tumors but Boosts Immunotherapy Paradox: Obesity Promotes Tumors but Boosts Immunotherapy
Obesity increases the risk for cancer, but, somewhat paradoxically, cancer patients who are obese and who undergo immunotherapy have better responses.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 28, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Adding Oncolytic Virus to Immunotherapy for Advanced Melanoma is Found to be Cost Prohibitive (CME/CE)
(MedPage Today) -- Combination treatment does not extend life and has little clinical benefit, cost-analysis finds (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 27, 2018 Category: American Health Source Type: news

One in Five Cancer Tumors Grow Before Shrinking: Nivolumab One in Five Cancer Tumors Grow Before Shrinking: Nivolumab
Immunotherapy can cause tumors to grow before they decrease in size, so patience is needed for the treatment to work, new research shows.Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - November 27, 2018 Category: Radiology Tags: Radiology News Source Type: news

Emerging Targets in Cancer Immunotherapy
Professor Lana E. Kandalaft,  PharmD, PhD spoke withCancer Network about the next generation of cancer immunotherapy. (Source: CancerNetwork)
Source: CancerNetwork - November 27, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news

Do Targeted Agents Aid Melanoma Immunotherapy?
Guy Ben-Betzalel, MD spoke withCancer Network about the emerging role of targeted BRAF+MEK inhibition in antitumor immunity. (Source: CancerNetwork)
Source: CancerNetwork - November 27, 2018 Category: Cancer & Oncology Authors: Bryant Furlow Source Type: news

Next Frontiers in Systemic Therapy for Soft Tissue Sarcoma Next Frontiers in Systemic Therapy for Soft Tissue Sarcoma
Molecularly targeted therapy and immunotherapy are changing the treatment landscape of soft tissue sarcoma.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 26, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Fred Hutch at ASH: Press briefing on CAR T-cell therapy, CRISPR for blood disorders, more
(Fred Hutchinson Cancer Research Center) Fred Hutchinson Cancer Research Center's latest findings on cancer immunotherapies, CRISPR for blood disorders, stem cell transplantation and insights on the immune system and cancer will be featured at the 60th annual meeting of the American Society of Hematology, which will be held Dec. 1-4 in San Diego. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 26, 2018 Category: Cancer & Oncology Source Type: news

Add new lung cancer treatment to Cancer Drugs Fund, says NICE
3000+ patients set to benefit from provisional thumbs up for immunotherapy drug Keytruda Related items fromOnMedica Is crowdfunding for cancer patients paying for ‘quackery’? Call for NHS England to ‘think again’ on limiting treatment Put case for adding leukaemia drug to Cancer Drugs Fund, NICE tells company Cancer patients using complementary meds die sooner NICE calls for safer use of controlled drugs (Source: OnMedica Latest News)
Source: OnMedica Latest News - November 23, 2018 Category: UK Health Source Type: news

OBI Pharma Granted FDA Orphan Drug Designation for OBI-888 for the Treatment of Pancreatic Cancer
First Orphan Drug Designation for OBI-888, a novel first-in-class Monoclonal Antibody targeting Globo H, a glycolipid antigen found on multiple tumor types. TAIPEI, Taiwan, Nov. 21, 2018 -- (Healthcare Sales & Marketing Network) -- OBI Pharma, Inc., a ... Biopharmaceuticals, Oncology, FDA OBI Pharma, Pancreatic Cancer, immunotherapy, Globo H (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 21, 2018 Category: Pharmaceuticals Source Type: news

Allergen Immunotherapy as Add-on to Biologic Agents Allergen Immunotherapy as Add-on to Biologic Agents
A new review examines recent evidence regarding the addition of biological treatments to allergen-specific immunotherapy. What have we learned?Current Opinion in Allergy and Clinical Immunology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 21, 2018 Category: Consumer Health News Tags: Allergy & Clinical Immunology Journal Article Source Type: news

New experimental drug offers hope for those with peanut allergies
An immunotherapy drug may allow allergy sufferers lead more normal lives. (Source: ABC News: Health)
Source: ABC News: Health - November 20, 2018 Category: Consumer Health News Tags: Health Source Type: news

AstraZeneca's Pivotal Lung Cancer Trial Fails Main Goal in Late Stage Trial AstraZeneca's Pivotal Lung Cancer Trial Fails Main Goal in Late Stage Trial
AstraZeneca said on Friday its immunotherapy drug Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 20, 2018 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Immunotherapy Side Effects May Be More Common Than Thought
TUESDAY, Nov. 20, 2018 -- Adverse events for immune checkpoint inhibitors used to treat non-small cell lung cancer (NSCLC) may be more common in real-world settings than reported in the clinical trials that led to U.S. Food and Drug Administration... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 20, 2018 Category: Pharmaceuticals Source Type: news

Stand Up to Cancer funds innovative approach to pancreatic cancer
(University of Texas M. D. Anderson Cancer Center) Research on a new way of deploying the immune system against pancreatic cancer, an exceptionally lethal cancer that has so far resisted new immunotherapies, will receive $1 million in initial funding from Stand Up to Cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 20, 2018 Category: International Medicine & Public Health Source Type: news

11 THINGS We ’ d Really like to know: How Can We Unleash the Immune System?
Although immunotherapy can work wonders for cancer, it does not help everyone, side effects can be fierce, and costs are high. But the field is young. (Source: NYT Health)
Source: NYT Health - November 20, 2018 Category: Consumer Health News Authors: DENISE GRADY Tags: Immune System Immunotherapy Drugs (Pharmaceuticals) Cancer Source Type: news

A New Peanut Allergy Drug Could Be a Promising Treatment for Children
A new drug could become the first-ever protective treatment for the more than one million children in the U.S. who suffer from peanut allergies. In a phase-three trial, the results of which were published in the New England Journal of Medicine, the peanut-derived drug AR101 helped some children with severe peanut allergies tolerate the equivalent of two peanut kernels without serious side effects. Prior to taking the drug, none of these children could safely ingest more than the equivalent of one-tenth of a kernel. AR101, which is manufactured by Aimmune Therapeutics (the company also designed and funded the study), delive...
Source: TIME: Health - November 19, 2018 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthytime Research Source Type: news

New Peanut Allergy Drug Shows Unprecedented Success New Peanut Allergy Drug Shows Unprecedented Success
Two-thirds of children and adolescents could tolerate two peanuts after a year of immunotherapy, results from the phase 3 PALISADE study show, which could protect them from accidental ingestion.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 19, 2018 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news